When Blood & Guidance Go Bad: The Story of Bacteremia as an Indication Janice Soreth, M.D. Director Division of Anti-Infective Drugs US Food & Drug Administration.

Slides:

Advertisements

Similar presentations

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.

Advertisements

Acute Otitis Media Trials: Evolution of Guidance Janice Soreth, M.D. Division of Anti-Infective Drug Products January 30, 2001.

1 Voriconazole NDAs and Empiric Antifungal Therapy of Febrile Neutropenic Patients Study 603 John H. Powers, M.D. Medical Officer Division.

Wes Theurer, DO.  Recognize sepsis early  Understand therapeutic principles  Cultures before antibiotics  Crystalloid fluid resuscitation  Antimicrobials.

Primary bloodstream infection as an indication: Regulatory perspective FDA/IDSA/ISAP Workshop April 15, 2004 David Ross, M.D., Ph.D.

ICORD 2009: Facilitating Cooperation in Regulatory Efforts Timothy Cote, MD MPH Director, FDA Office of Orphan Products Development, Food and Drug Administration,

Importance of Pharmacogenetics in Oncology Richard Pazdur, MD. Director Office of Oncology Drug Products Center for Drug Evaluation and Research Food and.

Special Topics in IND Regulation

Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.

SEPSIS Early recognition and management. Aims of the talk Understand the definition of sepsis and severe sepsis Understand the clinical significance of.

1 Catheter-Related Bloodstream Infection Guidance Revisited Janice Pohlman, M.D. FDA AIDAC Presentation October 14, 2004.

Eunice Huang, MD, MS APSA Education Day Palm Desert, CA May 22, 2011

C-1 Staphylococcus aureus Bacteremia and Endocarditis: A Bad Bug and A New Drug G. Ralph Corey M.D. Professor of Internal Medicine and Infectious Diseases.

Complications and principles of treatment of infective endocarditis incl. prognosis and antibiotic prophylaxis for endocarditis.

1 FDA Trial Design Requirements for CABP David M. Shlaes MD, PhD Anti-infectives Consulting, LLC Stonington, CT.

IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.

Center for Drug Evaluation and Research August 2005 Electroretinography: The FDA’s Viewpoint Wiley A. Chambers, MD Deputy Director Division of Anti-Infective.

Biotechnology Research Project by Anna Dong, Soojin Jeong, Reina Ooka -Stem Cells-

BIOE 301 Lecture Seventeen. Guest Speaker Jay Brollier World Camp Malawi.

1 Safety Pharmacology for Oncology Pharmaceuticals at CDER John K. Leighton Associate Director for Pharmacology CDER/OND/OODP.

A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,

1 FDA Trial Design Requirements for HABP/VABP David M. Shlaes MD, PhD Anti-infectives Consulting, LLC Stonington, CT.

Understanding the Pre-IDE Program: FDA Perspective

Bacteremia and CRBSI as Labeled BSI Indications: A Regulatory History Alfred Sorbello, DO Medical Officer CDER/Division of Anti-Infective Drug Products.

Development of Antibiotics for Otitis Media: Past, Present, and Future Janice Soreth, M.D. Director Division of Anti-Infective Drug Products.

Clinical Trials Considerations in Primary Bacteremia due to Staphylococcus aureus Clinical Trials Considerations in Primary Bacteremia due to Staphylococcus.

Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.

ISKANDER AL-GITHMI, MD, FRCSC Consultant Cardiothoracic Surgeon Assistant Professor of Surgery King Abdulaziz University ISKANDER AL-GITHMI, MD, FRCSC.

Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.

DOING PRECONCEPTIONAL HEALTH: LOCAL REALITIES Marjorie Angert, D.O., MPH, Director of Medical Affairs, Division of Maternal, Child and Family Health, Philadelphia.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Implications for clinical trials for diabetic foot infections (DFI) Anti-Infective Drugs Advisory Committee October 28, 2003 David Ross, M.D., Ph.D. Division.

BIOE 301 Lecture Seventeen. Progression of Heart Disease High Blood Pressure High Cholesterol Levels Atherosclerosis Ischemia Heart Attack Heart Failure.

Clinical Trials for Bloodstream Infection / Infective Endocarditis G. Ralph Corey, MD Vance Fowler, MD Duke Clinical Research Institute April 15, 2004.

How Clinicians Use Data For Clinical Decision Making March 5, 2003 Anti-Infective Drug Advisory Committee How Clinicians Use Data For Clinical Decision.

1 Observations from Past Approvals for Acute Bacterial Sinusitis Janice Pohlman, M.D. AIDAC Meeting, October 29, 2003.

Acute Otitis Media: Lessons Learned Thomas Smith, M.D. Division of Anti-Infective Drug Products.

1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.

Gülden Çelik. Learning Objectives At the end of this lecture, the student should be able to: Define bacteremia, fungemia, and sepsis List the main types.

Center for Drug Evaluation and Research March 6, 2005 Bacteremia and Endocarditis: Products and Guidance Janice Soreth, MD Director Division of Anti-Infective.

Catheter-Related Blood Stream Infections A Phase 2 Randomized, Controlled Trial of Dalbavancin vs. Vancomycin Tim Henkel, MD, PhD Executive VP and Chief.

In the Best Interests of the Public Health... Janice Soreth, M.D. Acting Director Division of Anti-Infective Drug Products CDER/FDA.

1 Antibiotic Resistance: An Update Janice Soreth, M.D. Director Division of Anti-Infective Drug Products February 20, 2002.

Ketek ™ (Telithromycin) NDA Efficacy Review John Alexander, M.D., M.P.H. Medical Team Leader Division of Anti-Infective Drug Products.

Infective Endocarditis

C-1 Safety Results S. aureus Bacteremia and Endocarditis Study Gloria Vigliani, M.D. Vice President, Medical Strategy Cubist Pharmaceuticals.

1 Developing drugs for resistant pathogens: Problems and possibilities David Ross, M.D., Ph.D. Anti-Infective Drugs Advisory Committee February 20, 2002.

Prevalence of Bacteremia in Low Risk Patients with Sickle Cell Disease and Fever Shashidhar Marneni, MD Fellow(1 st Year) Pediatric Emergency Medicine.

Complications in Patients with Valvular Lesions Infective Endocarditis Heart Failure Dysrhythmias Pulmonary Hypertension Systemic Emboli Acute Rheumatic.

Dr Michelle Webb Renal Consultant, Associate Medical Director Patient Safety, East Kent Hospitals University NHS Foundation Trust and Co-lead for Sepsis.

1 Review of Efficacy Data New Drug Application NDA /S-008 Cubicin® (daptomycin for injection) Alfred Sorbello, DO Medical Officer FDA, CDER Center.

Outline of Current Situation Survey on HIV/AIDS (Proposal) Ms. Keiko Dozono Director for AIDS and Emerging Infectious Disease Control Health and Safety.

1 Issues in Conduct of Catheter Related Infection (CRI) Studies Charles Knirsch, MD, MPH FDA Anti-infective Advisory Committee Meeting October 14, 2004.

Harm from Invasive Devices Dr. Eleri Davies, Faculty Lead HCAI.

A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,

All Hands Electronic Information Integrity Call White Paper An Introduction to the Current State of EMR – et.al. R. L. Chamberlain, Ph.D.

Genes in Life is a place to learn about all the ways genetics is a part of your life. On this site you will learn:   How.

Version: 27 May 2007 New Models for Collaboration: Patients as Drivers and Partners in Neurological Research Integrating Patient Input Within the Drug.

HEALTH PROMOTION.

Monitoring and Evaluation: A Review of Terms

Sepsis Surgeon Champions Talking Points

Balancing Pre and Postmarket Requirements Different Scenarios

CMS and FDA The History and Horizon of Regulatory Coordination

Evaluating Sepsis Guidelines and Patient Outcomes

Broadening Eligibility Criteria to Make Clinical Trials More Representative Joint Recommendations of the American Society of Clinical Oncology and Friends.

Regulatory Considerations for Coronary Drug Coated Balloons – FDA View

Treating Disease Learning Objectives: Describe how antibiotics work.

Mark Lobato, MD Division of TB Elimination

Antibiotics and painkillers

Presentation transcript:

When Blood & Guidance Go Bad: The Story of Bacteremia as an Indication Janice Soreth, M.D. Director Division of Anti-Infective Drugs US Food & Drug Administration

2 Soreth October 15, 2004 Outline of Today’s Talks The District, Rockville, and White Oak The District, Rockville, and White Oak Hollywood Hollywood The Washington Redskins The Washington Redskins National Hockey League (NHL) Lockout National Hockey League (NHL) Lockout Monday Morning Quarterbacking Monday Morning Quarterbacking Credits Credits

Soreth October 15, District of Columbia, pre Bacteremia, sepsis, bacteremic sepsis, septicemia, primary bacteremia, and secondary bacteremia discussions began a long time ago, since the FDA was located in the District of Columbia. Org chart: Bureau of Biological and Physical Sciences, Division of Pharmacology, Branch of Antibiotics My knowledge of this era is derivative.

Soreth October 15, Rockville: 1970s and 1980s Language for “bacteremia”, “septicemia” made it into package inserts. Org chart changed: Bureau of Biological & Physical Sciences/Div of Pharm → Bureau of Drugs & Biologics/Div of Anti-Infectives → Center of Drug Evaluation & Research/Div Division of Anti-Infectives then regulated antibiotics, antiparasitics, topicals, dermatologics, ophthalmologics, antifungals, TB drugs, antivirals ↓ split Division of Anti-Viral Drugs (1988)

Soreth October 15, Rockville: 1990s to present Anti- Infectives Ur-Division of Anti-Infectives Special Pathogens & Immunologics Anti-Virals

Soreth October 15, : White Oak

7 Soreth October 15, 2004 Hollywood: Nothing Is Impossible “…every scientist should remove the word ‘impossible’ from his lexicon.” Christopher Reeve ( )

Soreth October 15, Hollywood: Nothing Is Impossible   …except maybe when it comes to breakdown of the skin, invasion of the bloodstream, and infection of the patient, followed by cardiac arrest, heart failure, coma, and death.   Superman was no match for a bloodstream infection.

Soreth October 15, AIDAC Meeting: October 14, 2004 It takes extraordinary individuals to recognize that investment and effort in the discovery of new antibiotics, and in treatments for serious infections like S. aureus bacteremia, are worth it in the long run.

10 Soreth October 15, 2004 The Washington Redskins and Catheter-Related Infections Guidance What do Joe Gibbs and the FDA have in common? Just like Joe Gibbs, we thought we had put all the right pieces together with the CRBSI guidance. Just like Joe Gibbs, we watched as the Monster just wouldn’t get up.

Soreth October 15, CRBSI Guidance Discussed at AIDAC meeting 1999 US stats: K episodes per year Mortality 12-25% Definable case definition Sponsors now tell us there are numerous reasons why they have hit the boards. Don’t blame it on my heart, blame it on my youth.

Soreth October 15, NHL Lockout and S. aureus Bacteremia Success, beyond being tied to a salary cap, is determined not by knowing where the puck is…Success, beyond being tied to a salary cap, is determined not by knowing where the puck is… …rather, knowing where the puck is going to be, sometimes unpredictable.…rather, knowing where the puck is going to be, sometimes unpredictable. Increasing incidence of S. aureus bacteremia, paralleled by rise in infective endocarditis, foreshadows where major players need to position themselves to win.Increasing incidence of S. aureus bacteremia, paralleled by rise in infective endocarditis, foreshadows where major players need to position themselves to win.

Soreth October 15, Issues for Discussion Should primary bacteremia due to S. aureus (PBSA) be an indication? What exactly would a healthy development program look like? Should primary bacteremia due to S. aureus (PBSA) be an indication? What exactly would a healthy development program look like? What patient populations would be included in such a program? What patient populations would be included in such a program? Should endocarditis due to S. aureus be a separate indication? Should endocarditis due to S. aureus be a separate indication?

Soreth October 15, Issues for Discussion (continued) Should we grant a CRBSI indication in its own right? Or fold it into a more general experience (PBSA or Complicated Skin Infections)? Should we grant a CRBSI indication in its own right? Or fold it into a more general experience (PBSA or Complicated Skin Infections)? If separate, what additional information would you suggest be collected on treating serious S. aureus infections? If separate, what additional information would you suggest be collected on treating serious S. aureus infections?

Soreth October 15, Issues for Discussion (continued) What role do preclinical and early clinical studies play in setting the stage for later, larger clinical trials? What role do preclinical and early clinical studies play in setting the stage for later, larger clinical trials? Sweat the Small Stuff: How many positive blood cultures are required prior to study entry in a PBSA clinical trial ? Sweat the Small Stuff: How many positive blood cultures are required prior to study entry in a PBSA clinical trial ?

Soreth October 15, Issues for Discussion (continued) Screening patients for admission into clinical trials is complicated. Any thoughts as to a general approach? Screening patients for admission into clinical trials is complicated. Any thoughts as to a general approach?

17 Soreth October 15, 2004Credits AC Staff:Shalini Jain Office:Mark Goldberger John Powers Edward Cox Leo Chan Division:Lillian Gavrilovich Sumathi Nambiar Janice Pohlman Fred Sorbello